Trinseo PLC

TSEOQ
Country: United StatesPrice: $0.00Market Cap: $36,559

Investment snapshot

6%positive consensus
Scored 1d ago

Positive

1

BUY / PASS

Neutral / negative

1 / 14

NEUTRAL / FAIL

Median fair value

$59.25

+5924899.7% vs price

Models with upside

2 / 17

Positive margin of safety

Strongest signal

TSEOQ undervalued: all 2 models price fair value above $0.00 (median $59.25)

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2403 (Top 77.6%)FAILFAILFAILFAILFAILFAILFAILPASSFAILNEUTRALFAILFAILFAIL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/A+100.0%+100.0%N/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-13

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

TTM ended 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-13

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-13

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-13

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-13

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Where It Passes

  • Valuation models100% pass✓ 2▾

    TSEOQ undervalued: all 2 models price fair value above $0.00 (median $59.25)

    Munger fair value$64.14
    ✓Munger+100.0% margin vs $0.00
    Pabrai fair value$54.36
    ✓Pabrai+100.0% margin vs $0.00

Where It Falls Short

  • Valuation0% pass✓ 2✗ 26▾

    No clean pass — all 13 investors flag at least one valuation criterion

    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio
    ✗Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value-42.9%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-42.9%, ROC=-17.2%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    Price / Book Value per ShareN/A (negative BVPS)
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessOE Yield=-847222.2%
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldFCF Yield=-419595.7%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical Average
    ✗MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Price vs. Trailing Low100% of trailing low ($0.00)
    ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization-1466123.25%; #6324/6340 (top 99.7%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization-38225.8815; #6442/6449 (top 99.9%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change-298.4%
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+82370.9620; #5/5247 (top 0.1%)
    ✓OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization-952706.58%; #4510/4519 (top 99.8%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date-90.00%; #5989/6202 (top 96.6%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Efficiency0% pass✗ 11▾

    All 8 investors flag TSEOQ's efficiency

    Current Ratio1.13
    ✗Graham>= 2.0
    ROIC (3-5 yr avg)-7.2%
    ✗Buffett> 10%
    ROIC - WACC-17.2%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)-17.2%
    ✗Greenblatt> 25%
    Current Ratio Change YoY1.37 -> 1.21
    ✗PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY1.33x -> 1.30x
    ✗PiotroskiImproved YoY
    Current Assets / Current Liabilities1.13
    ✗Dreman> 1.5
    Return on Invested CapitalN/A (non-positive invested capital)
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-17.7%; FY2024: ROIC=-2.0%; FY2025: ROIC=-13.9%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/5 years above 12% (latest -13.9%)
    ✗SleepROIC > 12% in a majority of years
  • Profitability6% pass✓ 4✗ 31▾

    15 of 16 flag TSEOQ's profitability — Graham, Buffett, Lynch +12 more

    Positive EPS (10 years)8/15 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)8/15 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-1.2%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-8.5% (latest)
    ✗BuffettStable or rising over 10 years
    Free Cash Flow Proxy$-305.0M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROEN/A (negative equity)
    ✗Lynch> 15%
    EBIT / Enterprise Value-42.9%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-42.9%, ROC=-17.2%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-23.93%
    ✗PiotroskiROA > 0
    ROA Change YoY-13.18% -> -23.93% (delta: -10.75%)
    ✗PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=-4.49%, ROA=-23.93%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY7.6% -> 5.6%
    ✗PiotroskiImproved YoY
    Pre-Tax Income / Revenue-16.4%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity
    ✗Dreman> 12%
    Margin of Safety
    ✗PabraiP/B < 1.5 or P/E < 15
    Return on Equity-19.3% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency8/14 years positive
    ✓MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue-5.8%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-12.4% (2023) -> -8.5% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 3.9% -> 5.6%, operating margin -12.4% -> -8.5%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization-1466123.25%; #6324/6340 (top 99.7%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+9.88%; #2811/3702 (top 75.9%)
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.1202; #3700/5884 (top 62.9%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR10.7% over 5 years
    ✓Neff7%-20% annualized
    Positive Diluted-EPS Years6/10 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Verdicts6% pass✓ 1✗ 15▾

    Split decision: 14 FAIL · 1 PASS · 1 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (2/9)✗BuffettFAIL (0/9)✗LynchFAIL (1/7)✗GreenblattRank #2403✗PiotroskiFAIL (F-Score 1)✗DremanFAIL (1/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (2/5)✗AckmanFAIL (1/9)✓TempletonPASS (4/8)✗SleepFAIL (2/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (3/6)✗SchlossFAIL (1/7)✗OshaughnessyFAIL (Rank #713/963 (Top 74.0%))
  • Debt & Leverage8% pass✓ 2✗ 13▾

    11 of 12 flag TSEOQ's debt & leverage — Buffett, Lynch, Piotroski +8 more

    LT Debt vs Net Current AssetsLT Debt $1.5M vs NCA $131.0M
    ✓GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: N/A (negative equity), IC: -1.3x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / EquityN/A (negative equity)
    ✗Lynch< 0.33
    Cash - Long-term Debt$179.4M
    ✓LynchPositive preferred
    LT Debt / Total Assets Change83.23% -> 102.29%
    ✗PiotroskiDecreased YoY
    Current Assets / Current Liabilities1.13
    ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity
    ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
    Debt LevelsN/A (non-positive equity)
    ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=-1.3x, D/EBITDA=68.1x
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity
    ✗Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)
    ✗AsnessTop 30% of eligible cross-section
  • Cash Flow20% pass✓ 3✗ 9▾

    8 of 10 flag TSEOQ's cash flow — Buffett, Lynch, Piotroski +5 more

    Free Cash Flow Proxy$-305.0M
    ✗BuffettPositive and growing
    FCF Positive and Growing$-348.3M
    ✗LynchPositive and growing
    Operating Cash Flow$-102.4M
    ✗PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=-4.49%, ROA=-23.93%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    P/E or FCF YieldFCF Yield=-419595.7%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive11/14 years FCF positive
    ✓MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap-967500.0%
    ✗Ackman>= 4%
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency12/14 years positive
    ✓SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$-348.3M
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization-952706.58%; #4510/4519 (top 99.8%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Growth25% pass✓ 2✗ 11▾

    6 of 8 flag TSEOQ's growth — Graham, Lynch, Dreman +3 more

    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: 12.6% vs Rev: -3.9%
    ✗LynchInventory growth < Revenue growth
    EPS Growth Direction
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency8/14 years positive
    ✓MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth-15.3%
    ✗Ackman>= 5%
    Positive EPS Growth Frequency2/5 years with positive EPS growth
    ✗AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 3.9% -> 5.6%, operating margin -12.4% -> -8.5%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR1.6%
    ✗SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR10.7% over 5 years
    ✓Neff7%-20% annualized

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Chemicals
SIC Sector: Chemicals & Pharmaceuticals
Size: Micro Cap($36,559)
Revenue: $3.0B-15.3% YoY
Net Income: $545.6M-56.6% YoY

Financial Snapshot

Operating Margin-8.5%
Return on Equity49.7%
Debt / Equity-2.32
Current Ratio1.21
EPS (Diluted)$-15.24
Shares Retired−1.7% / −2.3% 2y

Similar Companies

CTA-PBEIDP, Inc.
$46.8B
CFCF Industries Holdings, Inc.
$18.3B
RPMRPM INTERNATIONAL INC/DE/
$13.2B
ESIElement Solutions Inc
$8.0B

Shareholder Return

Fiscal 2025

Issued 1.7% of shares last year, 2.3% issued over two.

Buybacks
—
Dividends
$1.2M

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, operating cash flow, depreciation amortization, capex, dividends paid.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex, dividends paid.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex, dividends paid.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-03-13
FY 2024
Sources
  • 10-K · 2025-02-27
FY 2023
Sources
  • 10-K · 2024-02-23
FY 2022
Sources
  • 10-K · 2023-02-27
FY 2021
Sources
  • 10-K · 2022-02-23
Market Cap$36.6Kcurrent------$16.2Mest.$146.6Mest.$208.5Mest.$947.4Mest.$1.9Best.
Revenue$3.0B↓4%$778.7M↑5%$845.4M↑8%$724.7M↓8%$3.0B↓15%$3.5B↓4%$3.7B↓26%$5.0B↑3%$4.8B
Operating Income-$176.0M↓31%$11.2M↑140%$100.0K↑100%-$23.6M↑19%-$254.2M↓453%-$46.0M↑90%-$455.4M↓25%-$363.9M↓179%$461.4M
Net Income-$536.0M↓30%-$49.1M↑55%-$119.6M↓13%-$115.9M↓47%-$545.6M↓57%-$348.5M↑50%-$701.3M↓63%-$430.9M↓198%$440.0M
EPS (Diluted)--$-1.34↑56%$-3.27↓11%$-3.20↓44%$-15.24↓55%$-9.86↑50%$-19.88↓66%$-11.99↓208%$11.12
Gross Margin8.1%↑30%6.8%↑36%11.8%↑153%8.5%↑5%5.6%↓26%7.6%↑95%3.9%↓29%5.5%↓62%14.5%
Operating Margin-5.8%↓36%1.4%↑138%0.0%↑100%-3.3%↑12%-8.5%↓553%-1.3%↑89%-12.4%↓69%-7.3%↓177%9.6%
ROE38.4%↓20%———49.7%↓12%56.2%↓79%261.7%↑355%-102.5%↓336%43.4%
Total Debt$591.1M↓77%$591.1M↓77%$591.5M↓76%$2.8B↑13%$2.5B↑6%$2.4B↑5%$2.3B↓1%$2.3B$2.3B
Shareholders' Equity-$1.4B↓62%-$1.4B↓62%-$1.3B↓80%-$1.2B↓80%-$1.1B↓77%-$619.9M↓131%-$268.0M↓164%$420.3M↓59%$1.0B
Current Ratio1.13↓17%1.13↓17%1.17↓18%0.29↓80%1.21↓12%1.37↓23%1.78↓12%2.02↓7%2.16
Debt / Equity-0.42↑86%-0.42↑86%-0.44↑87%-2.27↑37%-2.32↑40%-3.89↑55%-8.58↓256%5.51↑140%2.29
Operating Cash Flow-$299.7M↓651%$25.9M↑220%-$115.3M↓1796%-$232.9M↓111%-$102.4M↓621%-$14.2M↓110%$148.7M↑242%$43.5M↓90%$452.7M
Free Cash Flow-$348.3M↓262%$14.6M↑138%-$125.3M↓4077%-$244.2M↓105%-$153.4M↓98%-$77.5M↓198%$79.0M↑175%-$104.7M↓131%$335.0M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Chemicals

TSEOQ vs Peers — Financial Grading

Revenue$3.0BMedian
Net Income$545.6MBottom 25%
ROE49.7%Top 25%
D/E-2.32Top 25%
Op. Margin-8.5%Bottom 25%
Curr. Ratio1.21Bottom 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
EIDP, Inc.CTA-PB$46.8B$54.21——————2/95/92/70/3F-Score 14/11
CF Industries Holdings, Inc.CF$18.3B$125.09$7.1B$1.8B37.2%0.6632.5%3.373/94/95/73/3F-Score 88/11
RPM INTERNATIONAL INC/DE/RPM$13.2B$103.73$7.9B$661.4M20.0%0.77—1.683/92/93/71/3F-Score 67/11
Element Solutions IncESI$8.0B$33.08$2.6B$190.8M7.1%0.6113.4%3.682/92/91/71/3F-Score 56/11
NEWMARKET CORPNEU$6.5B$709.19$2.7B$418.7M23.5%0.5020.0%2.534/96/92/71/3F-Score 55/11
HEXCEL CORP /DE/HXL$6.0B$79.46$1.9B$109.4M8.7%0.799.1%2.262/92/93/70/3F-Score 64/11
ICL Group Ltd.ICL$5.8B$4.52$7.2B$226.0M3.8%0.468.1%1.335/94/92/70/3F-Score 45/11
BALCHEM CORPBCPC$5.5B$173.14$1.0B$154.8M12.3%0.1320.2%2.072/94/92/71/3F-Score 95/11